Overview

Rare Disease Genetic Testing Market is poised to value USD 1954.24 million by 2028 end at a CAGR of 13.9% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Rare Disease Genetic Testing  Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Rare Disease Genetic Testing  Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Rare Disease Genetic Testing  Market:
• Quest Diagnostics Inc.
• Centogene N.V.
• Invitae Corporation
• 3billion, Inc.
• Arup Laboratories
• Eurofins Scientific
• Strand Life Sciences
• Ambry Genetics
• Perkin Elmer, Inc.
• Macrogen, Inc.
• Baylor Genetics
• Color Genomics, Inc.
• Health Network Laboratories
• Preventiongenetics
• Progenity, Inc.
• Coopersurgical, Inc.
• Fulgent Genetics Inc.
• Myriad Genetics, Inc.
• Laboratory Corporation Of America Holdings
• Opko Health, Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Rare Disease Genetic Testing  Market Segmentation:
By Disease Type
• Neurological Disorders
• Immunological Disorders
• Hematology Diseases
• Endocrine & Metabolism Diseases
• Cancer
• Musculoskeletal Disorders
• Cardiovascular Disorders (CVDs)
• Dermatology Disease
• Others

By Technology
• Next-Generation Sequencing (NGS)
 o Whole Exome Sequencing (WES)
 o Whole Genome Sequencing (WGS)
• Array Technology
• PCR-based Testing
• FISH
• Sanger Sequencing
• Karyotyping

By Specialty
• Molecular Genetic Tests
• Chromosomal Genetic Tests
• Biochemical Genetic Tests

By End User
• Research Laboratories & CROs
• Diagnostic Laboratories
• Hospitals & Clinics

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Rare Disease Genetic Testing  Market By Disease Type, By Technology, By Specialty, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Disease Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Rare Disease Genetic Testing Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Rare Disease Genetic Testing Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Rare Disease Genetic Testing Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Rare Disease Genetic Testing Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Neurological Disorders
   7.2. Immunological Disorders
   7.3. Hematology Diseases
   7.4. Endocrine & Metabolism Diseases
   7.5. Cancer
   7.6. Musculoskeletal Disorders
   7.7. Cardiovascular Disorders (CVDs)
   7.8. Dermatology Disease
   7.9. Others

8. Rare Disease Genetic Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Next-Generation Sequencing (NGS)
      8.1.1. Whole Exome Sequencing (WES)
      8.1.2. Whole Genome Sequencing (WGS)
   8.2.Array Technology
   8.3.PCR-based Testing
   8.4.FISH
   8.5.Sanger Sequencing
   8.6.Karyotyping

9. Rare Disease Genetic Testing Market, By Specialty Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Molecular Genetic Tests
   9.2. Chromosomal Genetic Tests
   9.3. Biochemical Genetic Tests

10. Rare Disease Genetic Testing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Research Laboratories & CROs
    10.2. Diagnostic Laboratories
    10.3. Hospitals & Clinics

11. North America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Rare Disease Genetic Testing Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Quest Diagnostics Inc.
         17.1.1. Company Overview
         17.1.2. Disease Type Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
    17.2. Centogene N.V.
         17.2.1. Company Overview
         17.2.2. Disease Type Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
    17.3. Invitae Corporation
         17.3.1. Company Overview
         17.3.2. Disease Type Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
    17.4. 3billion, Inc.
         17.4.1. Company Overview
         17.4.2. Disease Type Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
    17.5. Arup Laboratories
         17.5.1. Company Overview
         17.5.2. Disease Type Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
    17.6. Eurofins Scientific
         17.6.1. Company Overview
         17.6.2. Disease Type Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
    17.7. Strand Life Sciences
         17.7.1. Company Overview
         17.7.2. Disease Type Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
    17.8. Ambry Genetics
         17.8.1. Company Overview
         17.8.2. Disease Type Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
    17.9. Perkin Elmer, Inc.
         17.9.1. Company Overview
         17.9.2. Disease Type Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
    17.10.Macrogen, Inc.
         17.10.1. Company Overview
         17.10.2. Disease Type Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview
    17.11.Baylor Genetics
         17.11.1. Company Overview
         17.11.2. Disease Type Portfolio
         17.11.3. SWOT Analysis
         17.11.4. Financial Overview
         17.11.5. Strategic Overview
    17.12.Color Genomics, Inc.
         17.12.1. Company Overview
         17.12.2. Disease Type Portfolio
         17.12.3. SWOT Analysis
         17.12.4. Financial Overview
         17.12.5. Strategic Overview
    17.13.Health Network Laboratories
         17.13.1. Company Overview
         17.13.2. Disease Type Portfolio
         17.13.3. SWOT Analysis
         17.13.4. Financial Overview
         17.13.5. Strategic Overview
    17.14.Preventiongenetics
         17.14.1. Company Overview
         17.14.2. Disease Type Portfolio
         17.14.3. SWOT Analysis
         17.14.4. Financial Overview
         17.14.5. Strategic Overview
    17.15.Progenity, Inc.
         17.15.1. Company Overview
         17.15.2. Disease Type Portfolio
         17.15.3. SWOT Analysis
         17.15.4. Financial Overview
         17.15.5. Strategic Overview
    17.16.Coopersurgical, Inc.
         17.16.1. Company Overview
         17.16.2. Disease Type Portfolio
         17.16.3. SWOT Analysis
         17.16.4. Financial Overview
         17.16.5. Strategic Overview
    17.17.Fulgent Genetics Inc.
         17.17.1. Company Overview
         17.17.2. Disease Type Portfolio
         17.17.3. SWOT Analysis
         17.17.4. Financial Overview
         17.17.5. Strategic Overview
    17.18.Myriad Genetics, Inc.
         17.18.1. Company Overview
         17.18.2. Disease Type Portfolio
         17.18.3. SWOT Analysis
         17.18.4. Financial Overview
         17.18.5. Strategic Overview
    17.19.Laboratory Corporation Of America Holdings
         17.19.1. Company Overview
         17.19.2. Disease Type Portfolio
         17.19.3. SWOT Analysis
         17.19.4. Financial Overview
         17.19.5. Strategic Overview
    17.20.Opko Health, Inc.
         17.20.1. Company Overview
         17.20.2. Disease Type Portfolio
         17.20.3. SWOT Analysis
         17.20.4. Financial Overview
         17.20.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures